Pacific Biosciences Of California (PACB) Short-term Investments (2010 - 2026)

Pacific Biosciences Of California's Short-term Investments history runs 17 years deep, the most recent figure standing at $219.7 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 22.81% year-over-year to $219.7 million in Q1 2026; TTM through Mar 2026 was $219.7 million, a 22.81% decrease from a year earlier, with the FY2025 full-year figure at $20000.0, down 97.1% from the prior year.
• Short-term Investments advanced to $219.7 million in Q1 2026 per PACB's latest filing, from $20000.0 in the prior quarter.
• Across five years, Short-term Investments topped out at $534.2 million in Q1 2022 and bottomed at $20000.0 in Q4 2025.
• The 5-year median for Short-term Investments is $284.6 million (2025), against an average of $277.1 million.
• Across the five-year window, Short-term Investments tumbled 99.93% in 2023 and jumped 136658.67% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $447.2 million in 2022, then tumbled by 99.93% to $300000.0 in 2023, then surged by 130.0% to $690000.0 in 2024, then plunged by 97.1% to $20000.0 in 2025, then jumped by 1098340.0% to $219.7 million in 2026.
• Per Business Quant, the three latest PACB Short-term Investments figures stand at $219.7 million (Q1 2026), $20000.0 (Q4 2025), and $242.2 million (Q3 2025).